PerkinElmer, Inc. (PKI) Insider Andrew Okun Sells 2,273 Shares of Stock
PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,273 shares of PerkinElmer stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Andrew Okun also recently made the following trade(s):
- On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00.
PerkinElmer, Inc. (NYSE:PKI) opened at $72.06 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a 52-week low of $53.16 and a 52-week high of $84.49. The stock has a market cap of $8,351.76, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.76.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 12th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio is 10.61%.
Several equities analysts recently commented on the stock. Robert W. Baird reiterated a “buy” rating and set a $88.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Monday, January 8th. Cowen reaffirmed a “hold” rating and issued a $84.00 target price on shares of PerkinElmer in a report on Friday, January 26th. Jefferies Group reiterated a “hold” rating and set a $70.00 price target on shares of PerkinElmer in a research report on Friday, October 20th. Finally, ValuEngine downgraded shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $76.85.
Large investors have recently made changes to their positions in the stock. Cutler Group LP raised its position in shares of PerkinElmer by 845.7% in the 4th quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 2,537 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of PerkinElmer by 53.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock valued at $170,000 after acquiring an additional 779 shares during the period. Waldron LP acquired a new stake in shares of PerkinElmer in the 3rd quarter valued at approximately $200,000. Seaward Management Limited Partnership acquired a new stake in shares of PerkinElmer in the 3rd quarter valued at approximately $202,000. Finally, Signition LP acquired a new stake in shares of PerkinElmer in the 4th quarter valued at approximately $207,000. Institutional investors and hedge funds own 90.98% of the company’s stock.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.